Skip to content

Study · Observational study · n = 1,325 · 2018

6 results

Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.

Simioni N, Berra C, Boemi M, Bossi AC, Candido R, Di Cianni G, Frontoni S, Genovese S, Ponzani P, Provenzano V, Russo GT, Sciangula L, Lapolla A, Bette C, Rossi MC

Acta diabetologica12 Mar 2018Cited by 19 (Europe PMC)

PMID29527621 (opens in a new tab)PMCIDPMC5959971 (opens in a new tab)DOI10.1007/s00592-018-1124-0 (opens in a new tab)PepBankPUB-29527621
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

AimsThere is an unmet need among healthcare providers to identify subgroups of patients with type 2 diabetes who are most likely to respond to treatment.MethodsData were taken from electronic medical records of participants of an observational, retrospective study in Italy. We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors. RECursive Partitioning and AMalgamation (RECPAM) analysis was used to identify distinct homogeneous patient subgroups with different odds of achieving the primary endpoint.ResultsData from 1325 patients were included, of which 577 (43.5%) achieved HbA1c reduction ≥ 1.0% point (10.9 mmol/mol) after 12 months. Logistic regression showed that for each additional 1% HbA1c at baseline, the odds of reaching this endpoint were increased 3.5 times (95% CI: 2.90-4.32). By use of RECPAM analysis, five distinct responder subgroups were identified, with baseline HbA1c and diabetes duration as the two splitting variables. Patients in the most poorly controlled subgroup (RECPAM Class 1, mean baseline HbA1c > 9.1% [76 mmol/mol]) had a 28-fold higher odds of reaching the endpoint versus patients in the best-controlled group (mean baseline HbA1c ≤ 7.5% [58 mmol/mol]). Mean HbA1c reduction from baseline was as large as - 2.2% (24 mol/mol) in the former versus - 0.1% (1.1 mmol/mol) in the latter. Mean weight reduction ranged from 2.5 to 4.3 kg across RECPAM subgroups.ConclusionsGlycaemic response to liraglutide is largely driven by baseline HbA1c levels and, to a lesser extent, by diabetes duration.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In 1325 adults with type 2 diabetes treated with liraglutide in routine care in Italy, 577 (43.5%) reached an HbA1c reduction of at least 1.0 percentage point after 12 months.

    In plain wordsIn routine care in Italy, 43.5% of 1325 adults with type 2 diabetes lowered HbA1c by at least 1.0 point on liraglutide after 12 months.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction of at least 1.0% point after 12 months
    Study

    n = 1,325

    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Responders
    43.5%
    HbA1c reduction >=1.0% point at 12 months

    Source sentences

    Summary
    Data from 1325 patients were included, of which 577 (43.5%) achieved HbA1c reduction ≥ 1.0% point (10.9 mmol/mol) after 12 months.
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.
  2. 02HumanObservational studyOther

    In adults with type 2 diabetes treated with liraglutide, each additional 1% of baseline HbA1c increased the odds of an HbA1c reduction of at least 1.0 percentage point 3.5 times (95% CI 2.90-4.32).

    In plain wordsIn adults with type 2 diabetes on liraglutide, a higher starting HbA1c was linked to a much higher chance of a clear HbA1c drop.

    Peptide
    Liraglutide
    Outcome
    Not applicableOdds of HbA1c response per 1% higher baseline HbA1c
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Odds ratio per 1% baseline HbA1c
    3.5 times
    HbA1c reduction >=1.0% point

    Source sentences

    Summary
    Logistic regression showed that for each additional 1% HbA1c at baseline, the odds of reaching this endpoint were increased 3.5 times (95% CI: 2.90-4.32).
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.
  3. 03HumanObservational studyOther

    In adults with type 2 diabetes treated with liraglutide, patients in the most poorly controlled subgroup had 28-fold higher odds of reaching the HbA1c endpoint than the best-controlled group.

    In plain wordsOn liraglutide, adults with the highest starting HbA1c were far more likely to reach the HbA1c target drop than those with the lowest.

    Peptide
    Liraglutide
    Outcome
    Not applicableOdds of HbA1c response, poorest-controlled versus best-controlled subgroup
    Study

    n: not reported in source

    Comparator
    Best-controlled subgroup (mean baseline HbA1c 7.5% or lower)
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Odds ratio
    28 fold
    RECPAM Class 1 vs best-controlled group

    Source sentences

    Summary
    Patients in the most poorly controlled subgroup (RECPAM Class 1, mean baseline HbA1c > 9.1% [76 mmol/mol]) had a 28-fold higher odds of reaching the endpoint versus patients in the best-controlled group (mean baseline HbA1c ≤ 7.5% [58 mmol/mol]).
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes treated with liraglutide, the mean HbA1c fell by as much as 2.2% from baseline in the most poorly controlled subgroup.

    In plain wordsIn the group with the highest starting HbA1c, liraglutide was followed by an HbA1c fall of as much as 2.2%.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean HbA1c reduction in the most poorly controlled subgroup
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean HbA1c change
    −2.2%
    RECPAM Class 1

    Source sentences

    Summary
    Mean HbA1c reduction from baseline was as large as - 2.2% (24 mol/mol) in the former versus - 0.1% (1.1 mmol/mol) in the latter.
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.
  5. 05HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes treated with liraglutide, the mean HbA1c fell by only 0.1% from baseline in the best-controlled subgroup.

    In plain wordsIn the group with the lowest starting HbA1c, HbA1c fell by only 0.1% after liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean HbA1c reduction in the best-controlled subgroup
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean HbA1c change
    −0.1%
    best-controlled subgroup

    Source sentences

    Summary
    Mean HbA1c reduction from baseline was as large as - 2.2% (24 mol/mol) in the former versus - 0.1% (1.1 mmol/mol) in the latter.
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.
  6. 06HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes treated with liraglutide, mean weight fell by 2.5 to 4.3 kg across the five RECPAM subgroups.

    In plain wordsIn adults with type 2 diabetes on liraglutide, average weight loss ranged from 2.5 to 4.3 kg across subgroups.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight reduction across RECPAM subgroups
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Mean weight reduction
    2.5 to 4.3 kg
    RECPAM subgroups

    Source sentences

    Summary
    Mean weight reduction ranged from 2.5 to 4.3 kg across RECPAM subgroups.
    2 context sentences
    Summary · context
    Data were taken from electronic medical records of participants of an observational, retrospective study in Italy.
    Summary · context
    We used logistic regression models to assess the odds of achieving glycated haemoglobin (HbA1c) reduction ≥ 1.0% point after 12-month treatment with liraglutide (primary endpoint), according to various patient-related factors.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.